Roles of fibroblast growth factor-inducible 14 in hepatocellular carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 6, 2013, Pages 3509-3514

  Li, Nan ^a   Hu, Wen Jun ^a   Shi, Jie ^a   Xue, Jie ^a   Guo, Wei Xing ^a   Zhang, Yang ^a   Guan, Dong Xian ^b   Liu, Shu Peng ^b   Cheng, Yu Qiang ^a   Wu, Meng Chao ^a   Xie, Dong ^c   Liu, Shan Rong ^b   Cheng, Shu Qun ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Fibroblast growth factor; Hepatocellular carcinoma; Inducible 14; Portal vein tumor thrombosis; Prognosis

Indexed keywords

EID: 84882702583     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.6.3509     Document Type: Article

References (29)

1. Ando T, Ichikawa J, Wako M, et al (2006). TWEAK/Fn14 interaction regulates RANTES production, BMP-2-induced differentiation, and RANKL expression in mouse osteoblastic MC3T3-E1 cells. Arthritis Res Ther, 8, R146.
2. Asrani K, Keri RA, Galisteo R, et al (2013). The HER2- and Heregulin beta1 (HRG)-inducible TNFR Superfamily Member Fn14 Promotes HRG-driven Cell Migration, Invasion and MMP9 Expression. Mol Cancer Res, 11, 393-404.
3. Bridges JF, Joy SM, Gallego G, et al (2011). Needs for hepatocellular carcinoma control policy in the Asia-Pacific region. Asian Pac J Cancer Prev, 12, 2585-91.
4. Brown SA, Richards CM, Hanscom H N, et al (2003). The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptorassociated factors 1, 2, 3 and 5 and mediates nuclear factorkappaB activation. Biochem J, 371, 395-403.
5. Bruix J, Sherman M (2005). Management of hepatocellular carcinoma. Hepatology, 42, 1208-36.
6. Dai Z, Liu YK, Cui JF, et al (2006). Identification and analysis of altered alpha1, 6-fucosylated glycoproteins associated with hepatocellular carcinoma metastasis. Proteomics, 6, 5857-67.
7. Feng SL, Guo Y, Factor VM, et al (2000). The Fn14 immediateearly response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol, 156, 1253-61.
8. Gu L, Dai L, Cao C, et al (2013). Functional expression of TWEAK and the receptor Fn14 in human malignant ovarian tumors: possible implication for ovarian tumor intervention. PLoS One, 8, e57436.
9. Han H, Bearss DJ, Browne LW, et al (2002). Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res, 62, 2890-6.
10. Kawakita T, Shiraki K, Yamanaka Y, et al (2005). Functional expression of TWEAK in human colonic adenocarcinoma cells. Int J Oncol, 26, 87-93.
11. Li H, Hu Y, Li N, Zhou Y (2012). Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses. Asian Pac J Cancer Prev, 13, 1589-93.
12. Li L, Yu C, Gao H, Li Y (2010). Argonaute proteins: potential biomarkers for human colon cancer. BMC Cancer, 10, 38.
13. Llovet JM, Di Bisceglie AM, Bruix J, et al (2008). Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst, 100, 698-711.
14. Meighan-Mantha RL, Hsu DK, Guo Y, et al (1999). The mitogeninducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem, 274, 33166-76.
15. Michaelson JS, Burkly LC (2009). Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway. Results Probl Cell Differ, 49, 145-60.
16. Michaelson JS, Cho S, Browning B, et al (2005). Tweak induces mammary epithelial branching morphogenesis. Oncogene, 24, 2613-24.
17. Poon RT, Ng IO, Lau C, et al (2002). Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol, 20, 1775-85.
18. Saitoh T, Nakayama M, Nakano H, et al (2003). TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem, 278, 36005-12.
19. Shi J, Lai EC, Li N, et al (2010). Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol, 17, 2073-80.
20. Tirnitz-Parker JE, Viebahn CS, Jakubowski A, et al (2010). Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology, 52, 291-302.
21. Tran NL, McDonough WS, Donohue PJ, et al (2003). The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol, 162, 1313-21.
22. Tran NL, McDonough WS, Savitch BA, et al (2006). Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res, 66, 9535-42.
23. Wang J, Liu Y, Wei MJ, et al (2013). Clinical correlations and prognostic relevance of Fn14 expression in breast carcinoma. Histol Histopathol.
24. Wang S, Jiang W, Chen X, et al (2012). Alpha-fetoprotein acts as a novel signal molecule and mediates transcription of Fn14 in human hepatocellular carcinoma. J Hepatol, 57, 322-9.
25. Wang S, Zhan M, Yin J, et al (2006). Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene, 25, 3346-56.
26. Watts GS, Tran NL, Berens ME, et al (2007). Identification of Fn14/ TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int J Cancer, 121, 2132-9.
27. Whitsett TG, Cheng E, Inge L, et al (2012). Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol, 181, 111-20.
28. Willis AL, Tran NL, Chatigny JM, et al (2008). The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res, 6, 725-34.
29. Zhao YM, Wang L, Dai Z, et al (2011). Validity of plasma macrophage migration inhibitory factor for diagnosis and prognosis of hepatocellular carcinoma. Int J Cancer, 129, 2463-72.